Compare ALAR & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | FHTX |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7M | 323.4M |
| IPO Year | 2018 | 2020 |
| Metric | ALAR | FHTX |
|---|---|---|
| Price | $7.12 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $14.00 | $11.50 |
| AVG Volume (30 Days) | 34.2K | ★ 102.4K |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | $24.51 | $8.89 |
| Revenue Next Year | $33.43 | $20.13 |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $5.50 | $3.27 |
| 52 Week High | $18.00 | $6.95 |
| Indicator | ALAR | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 34.32 |
| Support Level | $6.39 | $3.65 |
| Resistance Level | $7.69 | $5.82 |
| Average True Range (ATR) | 0.51 | 0.28 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 29.11 | 7.42 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.